ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för AZT-1152. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

20 träffar

Bibliografisk träff 2020-09-23

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.

Ryu S, Ohuchi M, Yagishita S, Shimoi T, Yonemori K, Tamura K, Fujiwara Y, Hamada A.

Sci Rep · research-article; journal article · DOI 10.1038/s41598-020-72665-5

Bibliografisk träff 2019-03-14

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.

Floc'h N, Ashton S, Ferguson D, Taylor P, Carnevalli LS, Hughes AM, Harris E, Hattersley M, Wen S, Curtis NJ, Pilling JE, Young LA, Maratea K, Pease EJ, Barry ST.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-18-0577

Bibliografisk träff 2019-01-01

Aurora kinase B inhibitor barasertib (AZD1152) inhibits glucose metabolism in gastric cancer cells.

He J, Qi Z, Zhang X, Yang Y, Liu F, Zhao G, Wang Z.

Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/cad.0000000000000684

Bibliografisk träff 2018-03-01

Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib.

Ivanova D, Zhelev Z, Lazarova D, Getsov P, Bakalova R, Aoki I.

Anticancer Res · journal article · DOI 10.21873/anticanres.12364

Bibliografisk träff 2017-03-14

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.

Floc'h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, Maratea K, Derbyshire N, Caddy J, Jacobs VN, Hattersley M, Wen S, Curtis NJ, Pilling JE, Pease EJ, Barry ST.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-16-0580

Bibliografisk träff 2016-08-05

Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.

Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA.

Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-16-0298

Bibliografisk träff 2016-04-01

Docosahexaenoic Acid Sensitizes Leukemia Lymphocytes to Barasertib and Everolimus by ROS-dependent Mechanism Without Affecting the Level of ROS and Viability of Normal Lymphocytes.

Zhelev Z, Ivanova D, Lazarova D, Aoki I, Bakalova R, Saga T.

Anticancer Res · journal article

Bibliografisk träff 2016-02-09

Aurora B inhibitor barasertib prevents meiotic maturation and subsequent embryo development in pig oocytes.

Ju S, Peng X, Yang X, Sozar S, Muneri CW, Xu Y, Chen C, Cui P, Xu W, Rui R.

Theriogenology · journal article · DOI 10.1016/j.theriogenology.2016.01.030

Bibliografisk träff 2015-12-01

2-Deoxy-D-glucose Sensitizes Cancer Cells to Barasertib and Everolimus by ROS-independent Mechanism(s).

Zhelev Z, Ivanova D, Aoki I, Saga T, Bakalova R.

Anticancer Res · journal article

Bibliografisk träff 2014-02-19

Structure of Aurora B-INCENP in complex with barasertib reveals a potential transinhibitory mechanism.

Sessa F, Villa F.

Acta Crystallogr F Struct Biol Commun · research-article; journal article · DOI 10.1107/s2053230x14002118

Bibliografisk träff 2013-06-10

Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.

Kantarjian HM, Sekeres MA, Ribrag V, Rousselot P, Garcia-Manero G, Jabbour EJ, Owen K, Stockman PK, Oliver SD.

Clin Lymphoma Myeloma Leuk · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1016/j.clml.2013.03.019

Bibliografisk träff 2013-05-12

Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.

Yamauchi T, Uzui K, Shigemi H, Negoro E, Yoshida A, Ueda T.

Cancer Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cas.12164

Bibliografisk träff 2013-04-19

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.

Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A, SPARK-AML1 Investigators.

Cancer · clinical trial, phase ii; comparative study; research-article; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1002/cncr.28113

Bibliografisk träff 2013-01-13

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JH.

Invest New Drugs · journal article · DOI 10.1007/s10637-013-9923-1

Bibliografisk träff 2012-08-04

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.

Dennis M, Davies M, Oliver S, D'Souza R, Pike L, Stockman P.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s00280-012-1939-2

Bibliografisk träff 2012-06-02

Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.

Schwartz GK, Carvajal RD, Midgley R, Rodig SJ, Stockman PK, Ataman O, Wilson D, Das S, Shapiro GI.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-012-9825-7

Bibliografisk träff 2011-10-05

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Löwenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H.

Blood · clinical trial, phase ii; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1182/blood-2011-07-366930

Bibliografisk träff 2011-06-16

P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.

Grundy M, Seedhouse C, Russell NH, Pallis M.

BMC Cancer · research-article; journal article · DOI 10.1186/1471-2407-11-254

Bibliografisk träff 2011-05-28

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

Keizer RJ, Zandvliet AS, Beijnen JH, Schellens JH, Huitema AD.

Invest New Drugs · research-article; evaluation study; journal article · DOI 10.1007/s10637-011-9694-5

Bibliografisk träff 2011-05-11

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.

Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, Uike N, Ando K, Kihara R, Tobinai K, Asou H, Hotta T, Miyawaki S.

Leuk Res · multicenter study; clinical trial, phase i; journal article · DOI 10.1016/j.leukres.2011.04.008